ANL 28.85 Increased By ▲ 0.50 (1.76%)
ASC 15.15 Increased By ▲ 0.01 (0.07%)
ASL 24.15 Increased By ▲ 0.50 (2.11%)
AVN 97.95 Increased By ▲ 2.35 (2.46%)
BOP 9.30 Increased By ▲ 0.10 (1.09%)
BYCO 10.35 Increased By ▲ 0.28 (2.78%)
DGKC 135.50 Increased By ▲ 3.00 (2.26%)
EPCL 49.98 Increased By ▲ 1.28 (2.63%)
FCCL 25.16 Increased By ▲ 0.61 (2.48%)
FFBL 25.22 Decreased By ▼ -0.41 (-1.6%)
FFL 16.04 Increased By ▲ 0.04 (0.25%)
HASCOL 11.07 Increased By ▲ 0.01 (0.09%)
HUBC 85.00 Increased By ▲ 0.80 (0.95%)
HUMNL 7.70 Increased By ▲ 0.43 (5.91%)
JSCL 25.75 Increased By ▲ 1.10 (4.46%)
KAPCO 37.45 Increased By ▲ 1.35 (3.74%)
KEL 4.17 Increased By ▲ 0.12 (2.96%)
LOTCHEM 15.13 Increased By ▲ 0.37 (2.51%)
MLCF 47.18 Increased By ▲ 1.18 (2.57%)
PAEL 39.40 Increased By ▲ 0.65 (1.68%)
PIBTL 12.04 Decreased By ▼ -0.01 (-0.08%)
POWER 10.65 Increased By ▲ 0.05 (0.47%)
PPL 91.00 Increased By ▲ 0.40 (0.44%)
PRL 26.69 Increased By ▲ 0.39 (1.48%)
PTC 9.05 Decreased By ▼ -0.09 (-0.98%)
SILK 1.45 Increased By ▲ 0.05 (3.57%)
SNGP 38.75 Decreased By ▼ -0.25 (-0.64%)
TRG 145.70 Increased By ▲ 6.95 (5.01%)
UNITY 32.90 Increased By ▲ 0.75 (2.33%)
WTL 1.61 Increased By ▲ 0.05 (3.21%)
BR100 4,959 Increased By ▲ 85.49 (1.75%)
BR30 25,734 Increased By ▲ 497.97 (1.97%)
KSE100 45,966 Increased By ▲ 603.04 (1.33%)
KSE30 19,199 Increased By ▲ 314.87 (1.67%)
World

India wants Pfizer to do local study for approval

  • As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial.
  • Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.
13 Jan 2021

NEW DELHI: Any vaccine maker, including Pfizer Inc, which has sought emergency-use authorisation for its COVID-19 shot in India, must conduct a local "bridging" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters.

Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca Plc and Oxford University, has done a similar study on more than 1,500 people over months before seeking and receiving emergency approval in the country.

Local media have reported that Pfizer had sought an exception when last month it became the first company to seek emergency-use approval in India for its vaccine already in use overseas. The company has not attended subsequent meetings called by India's drugs regulator.

"As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial," Vinod K. Paul, who heads a government panel on vaccine strategy, said in an interview in his office near the parliament building.

A Pfizer spokeswomen did not immediately respond to a request seeking comment.

Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.

No vaccine maker will be given indemnity by the government should something go wrong, Paul said. Serum Institute had written to the government seeking indemnity. AstraZeneca has said it has received such indemnity in many other countries.

India has also approved for emergency use a vaccine developed locally by Bharat Biotech.